Methylprednisolone for Knee Arthritis

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byAjay Premkumar, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Recruiting

Sponsor: Emory University

No Placebo Group

Prior Safety Data

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial is testing whether a short-term course of medication can reduce pain, nausea, and the need for opioids in patients after knee replacement surgery. The study involves patients who are having knee replacement surgery and aims to see if this medication can improve their recovery by reducing inflammation. Certain medications have been shown to improve recovery and reduce nausea in various surgical settings.

Research Team

Ajay Premkumar, MD

Principal Investigator

Emory University

Eligibility Criteria

This trial is for patients aged 18 to 95 who are undergoing their first total knee replacement due to severe knee arthritis. It's not suitable for those with other conditions that might affect the surgery or recovery.

Inclusion Criteria

I am having a knee replacement due to arthritis.

I am between 18 and 95 years old.

Exclusion Criteria

I am a minor and cannot legally consent for myself.

Subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures

I have a condition that weakens my immune system, and taking steroids could be harmful.

See 1 more

Treatment Details

Interventions

Methylprednisolone (Corticosteroid)

Trial OverviewThe study tests if a short-term steroid medication called Medrol Dose Pak can reduce pain, nausea, and opioid use after knee replacement surgery compared to standard post-surgery care.

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: Experimental Group: Medrol DoseExperimental Treatment1 Intervention

The perioperative Medrol dose treatment will consist of a course that lasts six days, with 24 milligrams administered on the first day, 20 milligrams on the second day, 60 milligrams on the third day, 12 milligrams on the fourth day, 8 milligrams on the fifth day, and 4 milligrams on the sixth day. Patients will then be followed up at the clinic for six weeks following their procedure to allow for clinical evaluation and to measure outcome variables.

Group II: Control Group: Standard of CareActive Control1 Intervention

Patients in this group will receive a single intraoperative dose of 10 mg intravenous dexamethasone (control group, IV dexamethasone is standard of care).